Eptifibatide Injection - Platelet Aggregation Inhibitor for ACS and PCI
ProcurenetShort description
Eptifibatide Injection: Platelet Aggregation Inhibitor
- Medicinal Class: Platelet aggregation inhibitor, ideal for treating acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) patients.
- Dosage Form: Available as a 20 mg/10 mL (2 mg/mL) single-dose vial.
- Effective Dose: Initial IV bolus of 180 mcg/kg, followed by a continuous infusion at a rate of 2 mcg/kg/min. Dose adjustments necessary for patients with renal function impairment.
- Key Features: Injection grade; Main sales markets include North America, Eastern Europe, Asia, Middle East.
- Composition: Contains the active ingredient eptifibatide, a potent competitor of the glycoprotein IIb/IIIa receptor on platelets.
- Storage: Should be stored in a controlled room temperature between 20°C to 25°C (68°F to 77°F); not to be frozen; protect from light.
- Common Side Effects: bleeding, thrombocytopenia, allergic reactions, hypotension, back pain, nausea, vomiting.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Eptifibatide Injection - A Robust Solution for Acute Coronary Syndrome and Percutaneous Coronary Intervention
Eptifibatide Injection is a potent platelet aggregation inhibitor designed primarily for the treatment of acute coronary syndrome (ACS) and patients undergoing percutaneous coronary intervention (PCI). Our advanced formulation comes with an assurance of quality and reliability, engineered to provide efficient and effective treatment options for these critical heart conditions.
The recommended dosage for this medication is an intravenous bolus of 180 mcg/kg, followed by an infusion at an intensity of 2 mcg/kg/min. However, for patients with a creatinine clearance rate less than 50 mL/min, it's advisable to reduce the infusion strength to 1 mcg/kg/min. The dosage forms and strengths offered include a 20 mg/10 mL (2 mg/mL) format in a single-dose vial.
Key features of our Eptifibatide Injection:
- Remarkable efficiency as a platelet aggregation inhibitor
- Decisive solution for acute coronary syndrome and percutaneous coronary intervention
- Formulated with precise potency for assured effectiveness
- Offered in injection grade quality
- Suitable for patients with various levels of creatinine clearance rates
Please note, professional oversight and advice are strongly recommended when administering this medication due to potential risk factors and patient-specific needs. Always refer to a healthcare professional before starting any new treatment.
